Adaptimmune Extends Funding Runway Ahead Of Clinical Results In Second Half

UK T-cell receptor biotech, Adaptimmune, has raised $100m from a direct offering of its ADSs as it prepares for the reporting of clinical response data later this year from early clinical studies in cancer patients.